25 APRIL 2017
SAB Biotherapeutics Names Christoph Bausch as Chief Science Officer
Biotech entrepreneur brings scientific research and product development to novel immunotherapy platform
Sioux Falls, SD, April 25, 2017 – SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company, today officially announced the hire of Christoph L. Bausch, Ph.D. as its Chief Science Officer (CSO).
Dr. Bausch joins SAB’s executive team as an experienced research scientist and business development executive who has led the successful discovery, development and commercialization of platform technologies. Former CSO, Dr. Jin-an Jiao, who helped establish SAB’s technology, has transitioned to a strategic consultant role for the company.
“I’ve spent my entire career looking at platform technologies in the bioscience space,” said Dr. Christoph Bausch. “SAB’s platform, which produces human polyclonal antibodies–mimicking our natural immune response–is pioneering a new way of treating a broad range of infectious diseases. It’s an amazingly powerful platform, and truly a disruptive technology–no ones doing this today.”
As CSO, Dr. Bausch is responsible for antibody and antigen production, quality control laboratories, research collaborations, grant funding and clinical studies.
“It’s a unique opportunity to step into a company at this stage. There’s been a lot of water under the bridge maturing and de-risking this innovative technology,” he added. “With the capable team and strategic focus, this platform is ready for commercial primetime.”
Prior to SAB, Dr. Bausch served in business development positions most recently for $7B global biorefining leader, Poet, LLC, where he structured strategic partnerships, prospected and vetted new technologies, and streamlined research and development. He also worked in both research and commercialization roles for Fortune 500 life science company, Sigma-Aldrich.
“We are excited to have Christoph join our research team. His experience in molecular genetics, microbiology and bioprocessing is a valuable asset as we pursue our internal antigen and vaccine development capabilities,” said Eddie Sullivan, Ph.D., president and CEO of SAB Biotherapeutics, Inc. “This ability will enable us to control quality and expedite commercialization of new products as we scale up manufacturing.”
While at Sigma-Aldrich, Dr. Bausch founded Nanopore Diagnostics, LLC, a next generation microbial diagnostic company, and Keion Group, LLC, which offers services to commercialize new technologies and start new businesses. In addition to his own ventures, he also serves as a strategic advisor for academic and industry groups applying his global experience to develop a robust infrastructure and biotech competency in the Midwest.
“Christoph’s demonstrated track record of building bench science into business will be valuable as we develop new products from our DiversitAb™ Platform,” added Sullivan. “He brings both a scientific and business lens with a strategic commercialization focus to the leadership team. He’s also an entrepreneurial kind of guy and out-of-the-box thinker; that really fits well with our culture.”
Dr. Bausch received his Ph.D. in Microbiology at The Ohio State University, Columbus, Ohio, completed Post Doctoral Training at the Stowers Institute for Medical Research, Kansas City, Missouri and earned an M.B.A. from St. Louis University, St. Louis, Missouri, in addition to a B.A. in Biology from the University of Nebraska-Lincoln, Lincoln, Nebraska.
“It’s exciting to join a company that is passionate and dedicated to accomplishing the extraordinary to make a difference in the lives of patients,” added Bausch. “I look forward to working with this bright and talented team to advance this groundbreaking technology.”
# # #
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB) is a clinical stage, biopharmaceutical company focused on the development of novel antibody therapeutics, utilizing some of the most advanced polyclonal antibody science in the world. The company is pioneering the first large-scale platform to create fully human immunoglobulins. Its natural production platform holds the potential to transform the treatment of public health problems, rare conditions, long-term diseases and global pandemic threats.
605/695.8350 / firstname.lastname@example.org